Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

NCT04692155 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped FDA hold

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Ublituximab
DRUG: Umbralisib

Sponsor

University of Alabama at Birmingham